Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?
Read More 6 minute read Pharma Industry News Why the EMA review of PolTREG-T1D could influence autoimmune cell therapy development PolTREG-T1D moves toward European Medicines Agency review. Discover how this TREG cell therapy could reshape treatment for autoimmune diseases. bySoujanya RaviMarch 14, 2026